title: Microsatellite instability, prognosis and metastasis in gastric cancers from a low-risk population.
abstract: We examined 169 cases of gastric adenocarcinoma for microsatellite instability (MSI), using a panel of 8 microsatellite markers. Of these cases, 142 were from the United States, a country of relatively low risk for gastric cancer. Comparing microdissected tumors to normal cells from the same patient, we classified tumors as being microsatellite-stable (MSS) or having a low frequency of MSI (MSI-L, up to 30% of markers different in the tumor) or a high frequency of MSI (MSI-H, 30% or more of markers different). Among our American cases, we identified 26 (18.2%) showing MSI-H and 15 (10.6%) showing MSI-L. Twenty cases were from Korean patients, and they showed no significant differences in proportions of MSI-H and MSI-L from the American cases. MSI-H tumors in the American patients were characterized by elevated frequencies of band shifts in repeat sequences of the BAX (50%), transforming growth factor-beta receptor type II (TGFbetaRII, 68.9%), beta(2)-microglobulin (21.4%) and E2F4 (51.7%) genes. Alterations in E2F4 in MSI-H tumors were always integral multiples of 3 nucleotides lost or gained, which would not cause a frameshift mutation, and within the range of normal polymorphisms for this sequence. North American patients (n = 127) with MSI-H and MSI-L tumors had a longer median survival of 541 days and 587 days, respectively, compared to 265 days for patients with MSS tumors (p = 0.027). This survival difference may result from a significantly greater tendency for metastases in the MSS group (p = 0.031).
authors.affiliation: Louisiana State University Health Sciences Center and Stanley Scott Cancer Center, New Orleans, LA 70112, USA. bschne1@LSUMC.edu
authors.forename: B G
authors.initials: BG
authors.lastname: Schneider
authors.forename: J C
authors.initials: JC
authors.lastname: Bravo
authors.forename: J C
authors.initials: JC
authors.lastname: Roa
authors.forename: I
authors.initials: I
authors.lastname: Roa
authors.forename: M C
authors.initials: MC
authors.lastname: Kim
authors.forename: K M
authors.initials: KM
authors.lastname: Lee
authors.forename: K T
authors.initials: KT
authors.lastname: Plaisance
authors.forename: C M
authors.initials: CM
authors.lastname: McBride
authors.forename: R
authors.initials: R
authors.lastname: Mera
mesh_terms: D006801:Humans; D018895:Microsatellite Repeats; D009362:Neoplasm Metastasis; D011379:Prognosis; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins / Q000235:genetics; D019253:Proto-Oncogene Proteins c-bcl-2; D000077294:Receptor, Transforming Growth Factor-beta Type II; D018125:Receptors, Transforming Growth Factor beta / Q000235:genetics; D013274:Stomach Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate; D051028:bcl-2-Associated X Protein; D001613:beta 2-Microglobulin / Q000235:genetics
chemical_list: C494826:BAX protein, human; D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D018125:Receptors, Transforming Growth Factor beta; D051028:bcl-2-Associated X Protein; D001613:beta 2-Microglobulin; D017346:Protein Serine-Threonine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II